AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03834142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSS-2 Bridge
Description: The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
Study NCT00381914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D / day
Study NCT00381914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 800 IU vitamin D / day
Study NCT00381914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 1200 IU vitamin D / day
Study NCT02256410 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
Study NCT04382521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Intervention
Description: Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
Study NCT04382521 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text Message Intervention
Description: Participants will undergo a three component intervention consisting of (1) daily, adaptive text messages related to Positive Psychology or health behaviors, (2) twice weekly text messages related to a specific health behavior goal, and (3) three brief check-ins (at baseline, week 4, and week 8 of the intervention) with a study staff member to discuss progress towards health behavior goals. During the brief check-ins, the study staff member will inquire about: (1) medical conditions, (2) adherence gaps, (3) personal health goals (including weight goals), (4) motivation, self-efficacy, and barriers to reaching health goals, (5) preferred activity types (e.g., walking), and (6) sources of sedentary time (e.g., computer, TV). This information will be added to the algorithm for each individual and we will deliver tailored daily text messages for our participants.
Study NCT05094479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health information delivered via health app
Description: Intervention group will use a health app with non-personalized information on health-promoting lifestyle habits during pregnancy. Control group will use a health app without health information. Intervention effects on the lifestyle habits (gestational weight gain, diet quality, physical activity) will be investigated.
Study NCT02231762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg
Description: Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
Study NCT02231762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
Study NCT02111655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Second generation surveillance of AVF
Description: Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound.
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: vital signs
Description: Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
Study NCT00743184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozarelix
Description: One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
Study NCT00743184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
Study NCT03080506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Description: Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
Study NCT05021666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study NCT05021666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB 718
Description: dose in the next group will be determined following a review of data from the previous group
Study NCT03293316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
Study NCT03293316 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Random Noise Stimulation
Description: The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
Study NCT02210624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYNR-CS inj.
Description: Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
Study NCT00706589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Initial dose : 2mg, Maximum dose : 20mg
Study NCT00706589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial dose: 2mg, Maximum dose:20mg
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vital signs
Description: Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: physical examination of AVF
Description: Predialysis physical examination of AVF every dialysis session.
Study NCT01325844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: 0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
Study NCT03008317 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PEEK
Description: a metallic denture base
Study NCT03008317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK
Description: a metallic denture base
Study NCT04206969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcultural psychotherapy
Description: In addition to usual care, the participants receive transcultural psychotherapy
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical examination of AVF
Description: Predialysis physical examination of AVF every dialysis session.
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ktv test
Description: Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
Study NCT03639818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual sessions of cognitive remediation
Description: The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
Study NCT04492592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: Workshop
Study NCT04492592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS/Texting
Description: SMS/Texting
Study NCT02418689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV120101 (Poziotinib)
Description: NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
Study NCT04556786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transitions of care
Description: The intervention was a pharmacist-led transitions of care program that include medication reconciliation, daily schedule for medication taking and medical condition monitoring, and follow-up phone calls from a pharmacist at 60- and 90-day post-discharge in addition to the usual care.
Study NCT03581591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
Study NCT01753297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin 11.25 mg
Description: Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
Study NCT00593905 — intervention group
Intervention type: DRUG
Intervention: Sitaxsentan
Description: Sitaxsentan sodium 100 mg tablet every morning
Study NCT00593905 — intervention group
Intervention type: DRUG
Intervention: Bosentan, Ambrisentan
Description: Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
Study NCT01119664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 721015
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ktv test
Description: Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: urea method
Description: Quarterly recirculation with urea method.
Study NCT02111655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: urea method
Description: Quarterly recirculation with urea method.
Study NCT04542668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cycling then running
Description: Ergometer cycling Treadmill running
Study NCT04542668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Running then cycling
Description: Treadmill running Ergometer cycling
Study NCT04542668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inotropy
Description: Adrenaline induced inotropy
Study NCT04542668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resting
Description: Subjects must be minimally physically active
Study NCT05563116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography coronary artery calcium (CAC) score (part of routine workup)
Description: Agatston method quantified coronary calcification. A prospectively ECG-triggered, non-contrasted CAC score used a non-enhanced low radiation cardiac CT scan provided onsite at both centers. Quantification of CAC was performed using a SOMATOM Definition Edge or SOMATOM Force (Siemens Medical Solutions) with standard mediastinal parameters (width, 350 Hounsfield units; level, 50 Hounsfield units), and according to the current guidelines for CAC scoring of non-contrast non-cardiac chest CT scans.
Study NCT02009293 — intervention group
Intervention type: OTHER
Intervention: Cough monitor
Description: questionnaires about cough and quality of life
Study NCT01741714 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham chiropractic manipulative therapy
Description: Sham manipulation
Study NCT01741714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic spinal manipulative therapy
Description: Chiropractic spinal manipulative therapy
Study NCT03090074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet regime
Description: Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
Study NCT03090074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type of psychological support
Description: Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
Study NCT00601861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-21
Description: Fixed and equal dose for s.c. injection, 3 times weekly
Study NCT01920763 — intervention group
Intervention type: OTHER
Intervention: Clinical Measurement
Description: No direct interventions; study is observational and clinical assessments only will be performed.
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given orally
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given orally or IV
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally or IV
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00343863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00343863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nausea and vomiting therapy
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nausea and vomiting therapy
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron hydrochloride
Description: Given IV
Study NCT00343863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies
Study NCT00343863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies
Study NCT04304794 — intervention group
Intervention type: PROCEDURE
Intervention: Administration of iodinated contrast media
Description: Each patient was exposed on iodinated contrast medium administered during computed tomography, coronary angiography or transcatheter aortic valve implantation.
Study NCT04304794 — intervention group
Intervention type: DRUG
Intervention: Prophylactic administration of antithyroid drugs before iodinated contrast media exposure
Description: 13 patients received thiamazole with (6 patients) or without (7 patients) sodium perchlorate, one day prior to iodinated contrast medium (ICM) and for at least 14 days after for thiamazole (20-40 mg/daily) and 10 days after for sodium perchlorate (900 mg/daily).
Study NCT03855202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBMNC
Description: autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
Study NCT03855202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PS+CBMNC
Description: autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
Study NCT03855202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PS
Description: PS,dose is 70mg/kg
Study NCT03855202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placeo
Description: 0.9% sodium chloride installation after 24 hours
Study NCT02876874 — intervention group
Intervention type: DRUG
Intervention: indocyanine green(ICG)
Description: ICG will be injected into the dorsal of hand/foot
Study NCT03527628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adriamycin
Description: 25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
Study NCT03527628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
Study NCT03131713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1000mg
Study NCT03864016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction and maintenance of anesthesia
Description: The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
Study NCT03864016 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Induction and maintenance of anesthesia
Description: The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
Study NCT03527628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vinblastine
Description: 6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
Study NCT04419207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Exhaled breath of each participant will be collected with air bags and directly detected by a high-resolution high-pressure photon ionization time-of-ﬂight mass spectrometry (HPPI-TOFMS).
Study NCT03527628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dacarbazine
Description: 375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: PO
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: PO
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: PO
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: IV
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: PO
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: PO
Study NCT02160301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: PO
Study NCT00569439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5NS
Description: 5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
Study NCT03527628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brentuximab Vedotin
Description: 1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
Study NCT03527628 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABVD
Description: All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
Study NCT01356732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
Study NCT01134926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 8oo mcg intravaginal, second dose after one day if there is no response
Study NCT01459367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.